USD 0.21
0 (0%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ASCLF | 0 | 13.5 | 20.9 | 38.4 | 38.7 | -13.4 | 4566.7 | -65 | -65 | -65 |
| S&P 500 | -0.7 | -1.2 | 1.5 | 6.5 | 11.2 | 31.1 | 26.1 | 89.2 | 189.3 | 33336.9 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ASCLF |
| name | Ascletis Pharma Inc. |
| price | 0.21 |
| changes percentage | 0 |
| change | 0 |
| day low | 0.18 |
| day high | 0.21 |
| year high | 0.27 |
| year low | 0.14 |
| market cap | 206783640 |
| price avg 50 | 0.17 |
| price avg 200 | 0.18 |
| exchange | PNK |
| volume | 50000 |
| avg volume | 1589 |
| open | 0.18 |
| previous close | None |
| eps | -0.03 |
| pe | -7 |
| earnings announcement | 2025-03-24T12:00:00.000+0000 |
| shares outstanding | 984684000 |
| timestamp | 2024-11-14 20:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 56596000 | 54090000 | 4.63 |
| gross profit | 25990000 | -24692000 | 205.26 |
| gross profit ratio | 0.46 | -0.46 | 200.60 |
| research and development expenses | 216781000 | 267102000 | -18.84 |
| operating expenses | 25990000 | 314937000 | -91.75 |
| interest income | 99278000 | 44162000 | 124.80 |
| interest expense | 144000 | 157000 | -8.28 |
| ebitda | -195065000 | -284495000 | 31.43 |
| ebitdaratio | -3.45 | -4.3 | 19.86 |
| operating income | -300208000 | -262817000 | -14.23 |
| operating income ratio | -5.3 | -4.86 | -9.17 |
| net income | -144715000 | -314843000 | 54.04 |
| net income ratio | -2.56 | -5.82 | 56.07 |
| eps | -0.13 | -0.29 | 55.17 |
Revenue Growth: revenue increased to 57 million in 2023 from 54 million in 2022 representing a change of 4.63%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 26 million in 2023 from -25 million in 2022 representing a change of 205.26%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 26 million in 2023 from 315 million in 2022 representing a change of -91.75%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Operating Income: Operating income increased to -300 million in 2023 from -263 million in 2022 representing a change of -14.23%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -0.13 in 2023 from -0.13 in 2022 representing a change of 55.17%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 217 million in 2023 from 267 million in 2022 representing a change of -18.84%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -195 million in 2023 from -284 million in 2022 representing a change of 31.43%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to -145 million in 2023 from -315 million in 2022 representing a change of 54.04%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023Q4 | 2023Q2 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 1395602 | 6709681 | -79.20 |
| gross profit | -2503925 | 4793557 | -152.24 |
| gross profit ratio | -1.79 | 0.71 | -351.13 |
| research and development expenses | 16466452 | 12532211 | 31.39 |
| operating expenses | 28821894 | 16383216 | 75.92 |
| interest income | 7584665 | 7621935 | -0.49 |
| interest expense | 10235 | 10099 | 1.35 |
| ebitda | -29962858 | -10302143 | -190.84 |
| ebitdaratio | -21.47 | -1.54 | -1,298.29 |
| operating income | -31325818 | -11589659 | -170.29 |
| operating income ratio | -22.45 | -1.73 | -1,199.49 |
| net income | -17725953 | -2389059 | -641.96 |
| net income ratio | -12.7 | -0.36 | -3,467.16 |
| eps | -0.02 | -0.0 | -672.73 |
Revenue Growth: revenue decreased to 1 million in 2023Q4 from 7 million in 2023Q2 representing a change of -79.2%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to -3 million in 2023Q4 from 5 million in 2023Q2 representing a change of -152.24%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 29 million in 2023Q4 from 16 million in 2023Q2 representing a change of 75.92%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -18 million in 2023Q4 from -2 million in 2023Q2 representing a change of -641.96%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.02 in 2023Q4 from -0.02 in 2023Q2 representing a change of -672.73%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 16 million in 2023Q4 from 13 million in 2023Q2 representing a change of 31.39%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -30 million in 2023Q4 from -10 million in 2023Q2 representing a change of -190.84%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -31 million in 2023Q4 from -12 million in 2023Q2 representing a change of -170.29%. The increase in operating income indicates better operational performance and increased profitability.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 2491009000 | 2657042000 | -6.25 |
| total liabilities | 148943000 | 117156000 | 27.13 |
| total equity | 2342066000 | 2539886000 | -7.79 |
| cash and cash equivalents | 330117000 | 2470834000 | -86.64 |
| short term investments | 1969286000 | 11200000 | 17,482.91 |
| long term investments | -1906262000 | 10818000 | -17,721.21 |
| total current assets | 2332756000 | 2544726000 | -8.33 |
| total non current assets | 158253000 | 112316000 | 40.90 |
| total current liabilities | 140679000 | 108189000 | 30.03 |
| total non current liabilities | 8264000 | 8967000 | -7.84 |
| common stock | 731000 | 742000 | -1.48 |
| retained earnings | -1174403000 | -1029688000 | -14.05 |
| total debt | 8416000 | 4237000 | 98.63 |
Total Assets: Total Assets decreased to 2,491 million in 2023 from 2,657 million in 2022 representing a change of -6.25%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 149 million in 2023 from 117 million in 2022 representing a change of 27.13%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 2,342 million in 2023 from 2,540 million in 2022 representing a change of -7.79%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 330 million in 2023 from 2,471 million in 2022 representing a change of -86.64%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 2,333 million in 2023 from 2,545 million in 2022 representing a change of -8.33%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 141 million in 2023 from 108 million in 2022 representing a change of 30.03%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 1 in 2023 from 1 in 2022 representing a change of -1.48%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -1,174 million in 2023 from -1,030 million in 2022 representing a change of -14.05%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 8 million in 2023 from 4 million in 2022 representing a change of 98.63%. This indicates an increase in overall debt burden.
Short Term Investments: Short Term Investments increased to 1,969 million in 2023 from 11 million in 2022 representing a change of 17482.91%. This indicates an increase in short-term investment holdings.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 2276064000 | 2276064000 | 0.00 |
| total liabilities | 95792000 | 95792000 | 0.00 |
| total equity | 2180272000 | 2180272000 | 0.00 |
| cash and cash equivalents | 342994000 | 342994000 | 0.00 |
| short term investments | 1744642000 | 1744642000 | 0.00 |
| long term investments | 70755000 | 70755000 | 0.00 |
| total current assets | 2115386000 | 2115386000 | 0.00 |
| total non current assets | 160678000 | 160678000 | 0.00 |
| total current liabilities | 86761000 | 86761000 | 0.00 |
| total non current liabilities | 9031000 | 9031000 | 0.00 |
| common stock | 689000 | 689000 | 0.00 |
| retained earnings | 0 | 0 | NaN |
| total debt | 8853000 | 0 | NaN |
Total Debt: Total Debt increased to 9 million in 2024Q2 from 0 million in 2024Q1 representing a change of nan%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| net change in cash | -73651000 | -1323643000 | 94.44 |
| operating cash flow | -144162000 | -142453000 | -1.20 |
| free cash flow | -163320000 | -156854000 | -4.12 |
| capital expenditure | -19158000 | -14401000 | -33.03 |
| depreciation and amortization | 18480000 | 30191000 | -38.79 |
| deferred income tax | 0 | 148890000 | -100.00 |
| stock based compensation | 1331000 | 3193000 | -58.32 |
| accounts payables | 0 | -29744000 | 100.00 |
| inventory | -8054000 | -12839000 | 37.27 |
| acquisitions net | 0 | 7331000 | -100.00 |
| investments in property plant and equipment | -6213000 | -14401000 | 56.86 |
| net cash used for investing activites | 149845000 | -1297387000 | 111.55 |
| debt repayment | -2391000 | 0 | NaN |
| common stock issued | 0 | 961000 | -100.00 |
| common stock repurchased | -78961000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -81496000 | -1419000 | -5,643.20 |
| cash at end of period | 330117000 | 403768000 | -18.24 |
| accounts receivables | 18444000 | 29744000 | -37.99 |
| cash at beginning of period | 403768000 | 1727411000 | -76.63 |
Net Change in Cash: Net Change in Cash increased to -74 million in 2023 from -1,324 million in 2022 representing a change of 94.44%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -19 million in 2023 from -14 million in 2022 representing a change of -33.03%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 1 million in 2023 from 3 million in 2022 representing a change of -58.32%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 30 million in 2022 representing a change of 100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 18 million in 2023 from 30 million in 2022 representing a change of -37.99%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -144 million in 2023 from -142 million in 2022 representing a change of -1.2%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -163 million in 2023 from -157 million in 2022 representing a change of -4.12%. This indicates a decrease in cash generated after accounting for capital expenditures.
| 2023Q4 | 2023Q2 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| operating cash flow | -10659285 | -9247200 | -15.27 |
| free cash flow | -13010707 | -9544552 | -36.32 |
| capital expenditure | -2351422 | -297352 | -690.79 |
| depreciation and amortization | 1362960 | 1287515 | 5.86 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 0 | 0 | NaN |
| accounts receivables | -90420 | 2632019 | -103.44 |
| accounts payables | -896682 | 550844 | -262.78 |
| inventory | -114466 | -995934 | 88.51 |
| acquisitions net | 16427 | 721.38 | 2,177.17 |
| investments in property plant and equipment | -2351422 | -297352 | -690.79 |
| net cash used for investing activites | 770113 | 19884063 | -96.13 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -9467340 | -1448959 | -553.39 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -9621771 | -1644453 | -485.10 |
| net change in cash | -25210905 | -9274248 | -171.84 |
| cash at end of period | 320627845 | 345838750 | -7.29 |
| cash at beginning of period | 345838750 | 355112998 | -2.61 |
Net Change in Cash: Net Change in Cash decreased to -25 million in 2023Q4 from -9 million in 2023Q2 representing a change of -171.84%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -11 million in 2023Q4 from -9 million in 2023Q2 representing a change of -15.27%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -13 million in 2023Q4 from -10 million in 2023Q2 representing a change of -36.32%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2023Q4 from 1 million in 2023Q2 representing a change of -262.78%. This indicates that the company has increased its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure decreased to -2 million in 2023Q4 from 0 million in 2023Q2 representing a change of -690.79%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2023Q4 from 3 million in 2023Q2 representing a change of -103.44%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.05 | 0.05 | 5.89 |
| net income per share | -0.13 | -0.29 | 53.48 |
| operating cash flow per share | -0.13 | -0.13 | -2.42 |
| free cash flow per share | -0.15 | -0.14 | -5.38 |
| cash per share | 2.14 | 2.28 | -6.24 |
| book value per share | 2.18 | 2.34 | -6.68 |
| tangible book value per share | 2.16 | 2.32 | -7.12 |
| shareholders equity per share | 2.18 | 2.34 | -6.68 |
| interest debt per share | 0.0 | 0.0 | -7.18 |
| market cap | 1282228040.66 | 4123604406.52 | -68.91 |
| enterprise value | 960527040.66 | 1657007406.52 | -42.03 |
| pe ratio | -8.86 | -13.1 | 32.35 |
| price to sales ratio | 22.66 | 76.24 | -70.28 |
| pocfratio | -8.89 | -28.95 | 69.27 |
| pfcf ratio | -7.85 | -26.29 | 70.14 |
| pb ratio | 0.55 | 1.62 | -66.28 |
| ptb ratio | 0.55 | 1.62 | -66.28 |
| ev to sales | 16.97 | 30.63 | -44.60 |
| enterprise value over ebitda | -4.92 | -5.82 | 15.46 |
| ev to operating cash flow | -6.66 | -11.63 | 42.72 |
| ev to free cash flow | -5.88 | -10.56 | 44.33 |
| earnings yield | -0.11 | -0.08 | -47.82 |
| free cash flow yield | -0.13 | -0.04 | -234.85 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 1.65 | 8.67 | -80.98 |
| current ratio | 16.58 | 23.52 | -29.50 |
| interest coverage | -2084.78 | -1673.99 | -24.54 |
| income quality | 1.0 | 0.45 | 120.17 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 1.11 | 0.29 | 287.62 |
| research and ddevelopement to revenue | 3.83 | 4.94 | -22.43 |
| intangibles to total assets | 0.01 | 0.01 | 69.51 |
| capex to operating cash flow | -0.13 | -0.1 | -31.46 |
| capex to revenue | 0.34 | 0.27 | 27.14 |
| capex to depreciation | 1.04 | 0.48 | 117.34 |
| stock based compensation to revenue | 0.02 | 0.06 | -60.16 |
| graham number | 2.57 | 3.9 | -34.11 |
| roic | -0.13 | -0.11 | -13.11 |
| return on tangible assets | -0.06 | -0.12 | 50.76 |
| graham net net | 2.01 | 2.2 | -8.80 |
| working capital | 2192077000 | 2436537000 | -10.03 |
| tangible asset value | 2315751000 | 2523327000 | -8.23 |
| net current asset value | 2183813000 | 2427570000 | -10.04 |
| invested capital | 2286669000 | 2526137000 | -9.48 |
| average receivables | 13939000 | 38739500 | -64.02 |
| average payables | 1892000 | 2094500 | -9.67 |
| average inventory | 13295000 | 38376000 | -65.36 |
| days sales outstanding | 25.83 | 161.1 | -83.97 |
| days payables outstanding | 7.74 | 14.52 | -46.71 |
| days of inventory on hand | 72.4 | 95.07 | -23.84 |
| receivables turnover | 14.13 | 2.27 | 523.70 |
| payables turnover | 47.16 | 25.13 | 87.66 |
| inventory turnover | 5.04 | 3.84 | 31.30 |
| roe | -0.06 | -0.12 | 50.15 |
| capex per share | 0.02 | 0.01 | 34.63 |
ROE: Return on Equity (ROE) increased to -0.06 on 2023-12-31 from -0.12 on 2022-12-31, representing a change of 50.15%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 16.58 on 2023-12-31 from 23.52 on 2022-12-31, representing a change of -29.50%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -8.86 on 2023-12-31 from -13.10 on 2022-12-31, representing a change of 32.35%. Indicating an increase in the relative valuation of the company's stock.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| ASCLF | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | 0 | 0 | NaN |
| operating cash flow per share | 0 | 0 | NaN |
| free cash flow per share | 0 | 0 | NaN |
| cash per share | 0 | 0 | NaN |
| book value per share | 0 | 0 | NaN |
| tangible book value per share | 0 | 0 | NaN |
| shareholders equity per share | 0 | 0 | NaN |
| interest debt per share | 0 | 0 | NaN |
| market cap | 0 | 0 | NaN |
| enterprise value | -334141000 | -342994000 | 2.58 |
| pe ratio | 0 | 0 | NaN |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | 0 | 0 | NaN |
| pfcf ratio | 0 | 0 | NaN |
| pb ratio | 0 | 0 | NaN |
| ptb ratio | 0 | 0 | NaN |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | 0 | 0 | NaN |
| ev to operating cash flow | 0 | 0 | NaN |
| ev to free cash flow | 0 | 0 | NaN |
| earnings yield | None | None | NaN |
| free cash flow yield | 0 | 0 | NaN |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 0 | 0 | NaN |
| current ratio | 24.38 | 24.38 | 0.00 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0 | 0 | NaN |
| dividend yield | None | None | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.01 | 0.01 | 0.00 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0 | 0 | NaN |
| roic | None | None | NaN |
| return on tangible assets | None | None | NaN |
| graham net net | 0 | 0 | NaN |
| working capital | 2028625000 | 2028625000 | 0.00 |
| tangible asset value | 2155855000 | 2155855000 | 0.00 |
| net current asset value | 2019594000 | 2019594000 | 0.00 |
| invested capital | 2118278999 | 2118278999 | 0.00 |
| average receivables | 0 | 2716000 | -100.00 |
| average payables | 464000 | 556500 | -16.62 |
| average inventory | 6484000 | 6277500 | 3.29 |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | None | None | NaN |
| inventory turnover | None | None | NaN |
| roe | None | None | NaN |
| capex per share | 0 | 0 | NaN |
Current Ratio: Current Ratio decreased to 24.38 on 2024-06-30 Q2 from 24.38 on 2024-03-31 Q1, representing a change of 0.00%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Negative Sentiment: Discounted Cash Flow value is -0.12 which is lower than current price 0.21, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-07 06:30:00
Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection , demonstrated a half-life of 21 days , supporting once-monthly administration in patients with obesity In multiple pre-clinical studies using the diet-induced obese (DIO) mouse model, ASC47 demonstrated healthy weight loss (muscle-preserving weight loss) Compared to semaglutide in a head-to-head pre-clinical study using a DIO mouse model, ASC47 reduced total fat mass (-63.5%), statistically and significantly more than semaglutide (-39.6%). In the same study, ASC47 statistically and significantly increased total muscle mass (+5.8%), while semaglutide decreased total muscle mass (-9.3%).
Sentiment: Positive
Publish Date: 2024-09-17 06:25:00
- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity - ASC30 is two- to threefold more potent, in vitro, than orforglipron and stimulated significantly greater insulin secretion when compared with orforglipron in non-human primates (NHPs) - ASC30 single dose subcutaneous injection demonstrated sustained weight loss over one month in NHPs supporting once-monthly administration in humans - ASC30 oral once-daily dosing demonstrated sustained weight loss in NHPs supporting once-daily oral administration in humans - Topline data from ongoing U.S. Phase I clinical trials of ASC30 once-monthly subcutaneous injection and once-daily oral tablet to treat obesity expected first quarter 2025 - ASC30 has the potential to be a first-in-class and best-in-class small molecule GLP-1R agonist to treat obesity given its superior NHP data, as well as once-monthly and once-daily dosing HONG KONG , Sept. 17, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical trials for ASC30, the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once monthly subcutaneously and once-daily orally for the treatment of obesity.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
